Smartkarma Daily Briefs

• TSMC reported Q225 revenues of $30.1 billion, up 44% YoY, up 17.8% QoQ and handily beating the high end of the $29.2 billion guidance.
• Full year 2025 guidance raised to 30% YoY growth, and that may still not be enough
• Resumption of H20 sales to China not yet baked into forecast, an army of ex Intel employees coming on the job market & potential Fx reversal are all possible tailwinds

• Samsonite (1910 HK), the world’s leading travel luggage manufacturer/retailer, is trading well below its historical metrics. 
• The share price is up ~30% from its recent low, but down ~22% YTD following a ~31% fall over a 10-day period in early-April, shortly after Trump’s “Liberation Day” speech. 
• Management initiated a US$200mn buyback program last August. Overhangs include tariff and weak retail market in Asia and North America. Plus short selling has touched an all-time high.

• Cochlear Limited recently announced its half-year results for fiscal year 2025.
• In its earnings call, the company disclosed a mixed performance across its business segments.
• On the positive side, the company reported a strong 13% growth in Cochlear implant revenue and an even stronger 22% growth in Acoustics revenue, leading to an overall net sales increase of 6% in constant currency.

• James Hardie Industries Plc demonstrated a mixed performance in its fiscal fourth quarter of 2025, underpinned by its strategic growth initiatives amidst challenging market conditions.
• Despite facing a softer demand environment and macroeconomic uncertainties, the company managed to achieve its financial targets, indicative of its strategic agility and operational discipline.
• On the positive side, James Hardie’s focus on strategic investments and scaling the organization has borne fruit.

• TotalEnergies’ Q2 2025 revenue is expected to drop 17.2% QoQ and 19.4% YoY. Similarly, its EPS is projected to drop 8.7% QoQ and 15.7% YoY.
• TotalEnergies is expected to post its weakest quarterly revenue and EPS reading since Q1 2021, as falling crude and LNG prices overshadow gains in refining.
• With 80% of earnings tied to upstream and LNG, even strong production and steady downstream performance leave little room for upside.

• Agilent is a leading provider of instruments, services, and consumables for labs in the life sciences, diagnostics, applied chemical markets, and R&D sectors
• With a market cap of $30 billion, Agilent was born within Hewlett Packard and spun off more than 25 years ago
• Agilent has a total addressable market of $160 billion and has a history dating back to 1938, starting as a testing instrument for audio equipment used by Disney in the production of Fantasia

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

• Northern Star Resources Ltd’s March 2025 quarterly results showcased a strong financial and operational performance, despite facing some operational challenges.
• The company generated robust net mine cash flow of $295 million, with positive contributions from all production centers.
• The gold price, exceeding AUD 5,000 per ounce, aided this financial strength, alongside the company’s low-risk mining jurisdictions in Western Australia and Alaska.

• IDC and Counterpoint released their 2Q25 smartphone estimates. Smartphone units increased 1-2% YoY. Best performer: Samsung +8% YoY, but this didn’t help 2Q operating profits. Vivo +5%, Apple +2%.
• The smartphone market is desperately flat – or in slow decline. Smartphone is 76% of revenues for Qualcomm, 57% for Mediatek, 50% Apple and Xiaomi, 35% Samsung, 31% TSMC. Problem?
• For Semiconductor firms (QCOM, MTK, TSM), chips ASP increases 10-15% at each generation, between node migration (N3, N2) and increasing AI functionalities. For hardware vendors (Apple, Samsung, Xiaomi), it’s worse.

• • The Paradox initial processing capacity is envisaged to be able to handle 5-10 mmcf/d.
• Our base case assumes a conservative 5 mmcf/d, although throughput capacity is expected to increase with the tie-in of additional wells, including 16-2LN-CC and 28-11.
• Notably, the plant’s initial capacity is below the production potential of the 36-2R well.

• Fisher & Paykel Healthcare’s recent financial results for the fiscal year ending March 31, 2025, reveal a balanced mix of robust growth and strategic challenges, providing a comprehensive overview of the company’s current performance and future outlook.
• On the positive front, the company reported operating revenue of $2.02 billion, marking a 16% increase from the previous year.
• This growth is primarily driven by broad-based expansion across its hospital consumables portfolio and significant contributions from the obstructive sleep apnea (OSA) masks.